Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
Seventeen patients with acute leukaemia refractory to conventional chemotherapeutic agents were treated with the adenosine deaminase inhibitor, 2'-deoxycoformycin (dCF). Of the twelve patients with acute lymphoblastic leukaemia of the thymic phenotype (Thy-ALL), seven went into complete remission after one or two courses of therapy. Two other (Thy-ALL) patients showed good partial response, and three were resistant to dCF. The five patients with acute leukaemia of other phenotypes had progression of disease despite treatment with dCF. Response to dCF can be predicted from the pattern of change in cellular nucleotide levels in blood and/or bone marrow blasts which have been treated in vitro with dCF and deoxyadenosine. The main adverse effects of dCF therapy were renal and liver dysfunction, conjunctivitis, and haemolysis.
D000208:Acute Disease; D000243:Adenosine Deaminase / Q000097:blood; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003070:Coformycin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D003231:Conjunctivitis / Q000139:chemically induced; D005260:Female; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007223:Infant; D007668:Kidney / Q000187:drug effects; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008099:Liver / Q000187:drug effects; D008297:Male; D015649:Pentostatin; D010641:Phenotype; D012263:Ribonucleosides / Q000627:therapeutic use*; D013601:T-Lymphocytes
D012263:Ribonucleosides; D003070:Coformycin; D015649:Pentostatin; D000243:Adenosine Deaminase